To illustrate this, a double-transgenic APP/PS1 AD model allowed researchers to inspect the effects of two different curcumin dosages, including a 160 ppm low dose and 1000 ppm high dose for a period of 6 months [156]. This evidence concerns the gene APP and Alzheimer disease.